Your session is about to expire
← Back to Search
Nivolumab + Trametinib (+/- Ipilimumab) for Colorectal Cancer (CheckMate 9N9 Trial)
CheckMate 9N9 Trial Summary
This trial is looking at a new combination treatment for people with colon or rectal cancer that has spread and who have already been treated.
CheckMate 9N9 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate 9N9 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533CheckMate 9N9 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had interstitial lung disease or pneumonitis.I have an autoimmune disease.My colorectal cancer has a BRAF V600 mutation.I am fully active or restricted in physically strenuous activity but can do light work.My cancer's microsatellite status was checked using standard methods.I have been treated with drugs targeting the immune system and MEK enzymes.My colorectal cancer is confirmed to be in stage IV and has been previously treated.I have cancer that can be measured and has grown after radiation.I have active cancer spread to my brain or its coverings.I haven't taken high-dose steroids or other immune-weakening drugs in the last 2 weeks.
Frequently Asked Questions
What are the main purposes that Nivolumab is used for?
"Nivolumab is the standard of care for treating unresectable melanoma. Additionally, Nivolumab has shown to be effective in other cases such as squamous cell carcinoma, high risk of recurrence, and disease."
What is the past research on Nivolumab's efficacy?
"Nivolumab was originally studied in the year 2009 at Texas Children's Hospital. So far there have been 510 completed trials. There are currently 933 active trials, with a large number of these trials being performed out of Montreal, Quebec."
Are we still looking for volunteers for this experiment?
"That is correct. The clinical trial, which was originally posted on February 1st, 2018 and edited most recently on November 14th, 2022, is looking for 232 patients at 33 locations, according to the data available on clinicaltrials.gov."
In how many different medical clinics is this trial being run today?
"Patients can enroll at many locations, some of which include Local Institution in Montreal, Baylor Scott & White Medical Center - Temple-Division of Hematology/Oncology in Temple, Texas and Local Institution - 0113 in Edmonton, Alberta."
How many people are sign ups for this experiment?
"In total, 232 individuals that meet the pre-determined requirements are necessary for this clinical trial. Local Institution in Montreal, Quebec and Baylor Scott & White Medical Center - Temple-Division of Hematology/Oncology in Temple, Texas are two sites where patients can participate."
Share this study with friends
Copy Link
Messenger